| Ytd | 39.59% | |
| 1y | 12.89% |
| Open | 14.95 | Prev Close | 14.88 | Low | 14.59 | High | 15.79 | Mkt Cap | 2.37B |
| Vol | 4.74M | Avg Vol | 2.77M | EPS | -5.57 | P/E | N/A | Forward P/E | -8.09 |
| Beta | 3.31 | Short Ratio | 8.46 | Inst. Own | 97.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 11.09 | 200-d Avg | 11.58 | 1yr Est | 21.94 |
Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discover
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-li
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Mon
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underper
BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degr
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a ne
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company f